

November 12, 2021



# Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference

NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- **Immunovant, Inc.** (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will provide a corporate overview at the Stifel 2021 Virtual Healthcare Conference, taking place November 15-17, 2021.

## Stifel 2021 Virtual Healthcare Conference Presentation

Date: Wednesday, November 17<sup>th</sup>, 2021  
Time: 2:00pm Eastern Time  
Webcast: The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company's website, located at [www.immunovant.com](http://www.immunovant.com)

## About Immunovant, Inc.

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Immunovant is developing IMVT-1401 (batoclimab), a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.

## Contact:

Tom Dorney, MS, MBA  
Director, Investor Relations & Strategy  
Immunovant, Inc.  
[info@immunovant.com](mailto:info@immunovant.com)



Source: Immunovant